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Children with uncomplicated severe acute malnutrition (SAM) are treated at home with
ready-to-use therapeutic foods (RUTFs). The current RUTF dose is prescribed according to
the weight of the child to fulfil 100% of their nutritional needs until discharge. However, there
is doubt concerning the dose, as it seems to be shared, resulting in suboptimal cost-effi-
ciency of SAM treatment. We investigated the efficacy of a reduced RUTF dose in commu-
nity-based treatment of uncomplicated SAM.
Methods and findings
We undertook a randomised trial testing the non-inferiority of weight gain velocity of children
with SAM receiving (a) a standard RUTF dose for two weeks, followed by a reduced dose
thereafter (reduced), compared with (b) a standard RUTF dose throughout the treatment
(standard). A mean difference of 0.0 g/kg/day was expected, with a non-inferiority margin
fixed at −0.5 g/kg/day. Linear and logistic mixed regression analyses were performed, with
study site and team as random effects. Between October 2016 and July 2018, 801 children
with uncomplicated SAM aged 6–59 months were enrolled from 10 community health cen-
tres in Burkina Faso. At admission, the mean age (± standard deviation [SD]) was 13.4
months (±8.7), 49% were male, and the mean weight was 6.2 kg (±1.3). The mean weight
gain velocity from admission to discharge was 3.4 g/kg/day and did not differ between study
arms (Δ 0.0 g/kg/day; 95% CI −0.4 to 0.4; p = 0.92) confirming non-inferiority (p = 0.013).
However, after two weeks, the weight gain velocity was significantly lower in the reduced
dose with a mean of 2.3 g/kg/day compared with 2.7 g/kg/day in the standard dose (Δ −0.4
g/kg/day; 95% CI −0.8 to −0.02; p = 0.041). The length of stay (LoS) was not different (p =
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0.73) between groups with a median of 56 days (interquartile range [IQR] 35–91) in both
arms. No differences were found between reduced and standard arm in recovery (52.7%
and 55.4%; p = 0.45), referral (19.2% and 20.1%; p = 0.80), defaulter (12.2% and 8.5%; p =
0.088), non-response (12.7% and 12.5%; p = 0.95), and relapse (2.4% and 1.8%; p = 0.69)
rates, respectively. However, the reduced RUTF dose had a small 0.2 mm/week (95% CI
0.04 to 0.4; p = 0.015) negative effect on height gain velocity with a mean height gain of 2.6
mm/week with reduced and 2.8 mm/week with standard RUTF dose. The impact was more
pronounced in children under 12 months of age (interaction, p = 0.019) who gained 2.8 mm/
week with reduced and 3.1 mm/week with standard dose (Δ −0.4 mm/week; 95% CI −0.6 to
−0.2; p < 0.001). Limitations include not blinding participants to the RUTF dose received and
excluding all children with negative appetite test. The results are generalisable for relatively
food secure contexts with a young SAM population.
Conclusions
Reducing the RUTF dose provided to children with SAM after two weeks of treatment did
not reduce overall weight or mid-upper arm circumference (MUAC) gain velocity nor affect
recovery or lengthen treatment time. However, it led to a small but significant negative effect
on linear growth, especially among the youngest. The potential effect of reducing the RUTF




Why was this study done?
• Severe acute malnutrition (SAM) affects 19 million children worldwide and is treated
with ready-to-use therapeutic foods (RUTFs).
• The current RUTF formulation and dosage are based on an inpatient treatment model
and aim at achieving fast weight gain and recovery.
• However, when used in a home-based setting, the RUTF dose prescribed is often con-
sidered too large, resulting in sharing and a suboptimal cost-efficiency of SAM
treatment.
• We sought to investigate the efficacy of reducing the RUTF dosage used in community-
based treatment of uncomplicated SAM.
What did the researchers do and find?
• We conducted a randomised controlled trial testing the non-inferiority of a reduced
RUTF dose in the management of uncomplicated SAM compared with standard dose.
This was called the MANGO trial.
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• We enrolled 801 children 6–59 months of age and randomised them individually into
receiving (1) a standard dose of RUTF throughout the treatment and (2) a standard
dose during the first two weeks, followed by a reduced dose from third treatment week
onwards.
• The trial showed non-inferior weight gain velocity from admission to discharge and
similar recovery and length of stay in treatment.
• However, the reduced dose also resulted in a significantly slower height gain velocity
compared with the standard dose.
What do these findings mean?
• Our findings suggest that the reduction of the RUTF dose after the first two weeks
results in similar weight gain velocity and recovery rates as with the standard dose given
throughout SAM treatment.
• However, the reduced RUTF dose seems to slow down the height gain velocity of chil-
dren and might thus not be fully optimal for children’s healthy growth.
• The reduced dose approach should be tested in a routine programmatic setting and in
different food security contexts before scale-up.
Introduction
Worldwide, 19 million children under 5 years of age suffer from severe acute malnutrition
(SAM), contributing to over 500,000 deaths per year [1]. According to the World Health Orga-
nization (WHO) guidelines for community-based management of acute malnutrition
(CMAM), children without medical complications at admission are treated as outpatients,
with weekly checkup visits [2]. Treatment consists of a systematic antibiotic regimen, as well as
a ready-to-use therapeutic food (RUTF), prescribed according to the weight of the child and
continued until discharge [2].
RUTFs are highly fortified energy dense pastes that are designed to fulfil 100% of the nutri-
tional needs of children during the recovery from SAM [3]. In theory, the prescribed dose
should enable weight gains up to 20 g/kg/day, as observed in inpatient treatment of SAM with
RUTFs [4]. However, high weight gain rates have never been observed in community settings
where the average ranges between 1.0 and 5.5 g/kg/day using RUTFs [5–19], suggesting a
lower intake of the therapeutic product in home-based treatment. Several studies have sus-
pected or reported product sharing within and outside the household [8,13,20] as a reason for
lower weight gain.
The perceived high cost and large quantity of RUTFs administered [20–25] have sparked
attempts to optimise the product formulation and use [11,26–28]. One cluster-randomised
trial in Sierra Leone gradually reduced the RUTF dose of children recovering from SAM when
they reached moderate acute malnutrition (MAM) criteria [28]. However, the use of different
recovery criteria between intervention and control groups limits the interpretation of the
results. A retrospective analysis of a CMAM program in Myanmar, where, due to RUTF short-
age, the dose was reduced once children with SAM reached MAM status, showed high recov-
ery rates (90.2%). The lack of a control group in the study limits the interpretability of data
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[18]. To our knowledge, no rigorous clinical trial looking at the efficacy of reducing the RUTF
dose among children with SAM has been conducted. Reducing the RUTF dose given to chil-
dren treated for SAM in a cost restrained setting could enable the management of more mal-
nourished children with the same resources.
The present study aimed to test, in a non-inferiority randomised controlled design, the
impact of reducing the RUTF dose, after two weeks, on the weight gain velocity of children
treated for uncomplicated SAM in the community. The reduction aimed to support weight
gain rates of 5 g/kg/day and simplify the distribution and use of RUTF by children with SAM
to 1 or 2 daily sachets for children <7 kg and�7 kg, respectively.
Methods
Ethics
The study was performed in accordance with the principles in the Declaration of Helsinki. The
research protocol obtained ethical clearance from the national ethics committee (Comite´
d’e´thique pour la recherche en sante´ [CERS]) and the clinical trials board (Direction Ge´ne´rale
de la Pharmacie, du Me´dicament et des Laboratoires [DGPML]) of Burkina Faso. An indepen-
dent Data Safety Monitoring Board composed of one paediatrician and one statistician was
responsible for monitoring serious adverse events and conducted five complete data reviews
during the course of the study. Caregivers provided verbal and written consent prior to enrol-
ment and were made aware of their right to withdraw from the study at any time. Caregivers
in both arms were given an instant photo of their child at the end of the treatment period and
a bucket with soap at the end of the 3-month post-discharge follow-up period to compensate
for the time spent on study procedures.
Study design
We conducted a randomised controlled clinical trial (called MANGO) comparing the efficacy
of a reduced RUTF dose to a standard RUTF dose in the management of uncomplicated SAM
in children 6–59 months of age in a non-inferiority design.
Study setting and participants
The study was conducted in the Fada N’Gourma health district located in the Eastern region
of Burkina Faso. Malaria is endemic, with 69.3% of children presenting a positive rapid test
[29]. HIV prevalence is 1.0% among 15–49-year-olds. In 2016, the prevalence of severe wasting
(weight-for-height z-score [WHZ] <−3) and moderate wasting (WHZ between −3 and −2)
was 2.4% and 8.6%, respectively [30]. There were 42 health centres in the district in 2015, all
run by the Ministry of Health and supported by Action Against Hunger; 10 were chosen as
study sites based on criteria on minimum SAM caseload (>7 new SAM admissions/month),
accessibility, and a suitable schedule to couple study visit days with routine growth monitoring
days.
Between October 2016 and July 2018, study participants were selected from children pre-
senting with SAM at the 10 participating health centres for curative and preventive activities.
Study staff checked admission criteria: WHZ <−3 and/or mid-upper arm circumference
(MUAC) <115 mm, positive appetite test (performed as per the national protocol [31]), no
oedema or medical complications, and between 6 and 59 months of age. Exclusion criteria
included having received treatment for SAM within 6 months, caregiver planning to travel or
unable to comply with the weekly checkup schedule, peanut or milk allergy, or disability affect-
ing food intake. Children with any grade of oedema or medical complications, as defined by
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the Burkina national protocol for CMAM [31], at any time during the study were referred to
inpatient care.
Randomisation
Randomisation was stratified by health centre using varying block sizes from 2 to 8. Randomisa-
tion lists were generated using the website www.randomization.com. After confirming eligibil-
ity and obtaining consent from the caregiver, children were given a unique study identifier (ID)
by a team supervisor and assigned to a treatment group. Only the RUTF distributors had access
to the randomisation lists, while staff involved in assessing the eligibility and study outcomes of
the child were blinded to the trial arm. Participants could not be blinded to the RUTF dose
received. Investigators remained blinded to treatment groups until the final analysis stage.
Study visits and procedures
Upon admission, the child’s caregiver was interviewed regarding household socioeconomic
characteristics, care practices, and recent morbidity of the child and encouraged to adhere to
weekly visits until recovery. Anthropometric measurements and a clinical examination were
performed at each visit from admission to discharge. As per national SAM treatment protocol,
seven key messages were delivered to caregivers in both groups, including advice to continue
breastfeeding and to offer family foods in addition to RUTF if needed.
Anthropometrics were measured in duplicate at each visit: weight using an electronic scale
(SECA 876, SECA, Hamburg, Germany) to the nearest 100 g, height (recumbent for<24
months of age; standing for�24 months of age) using a wooden measuring board (locally
made) to the nearest 1 mm, and MUAC using a non-stretchable colourless measuring tape to
the nearest 1 mm. Using WHO field tables, WHZ was determined and used for admission and
discharge. In later analysis, WHZ was calculated using the package ‘zscore06’ [32] in STATA
15 (StataCorp, College Station, TX).
Children were followed up until recovery. Children missing their study visit were contacted
either directly by telephone or via a community health worker and encouraged to return. Chil-
dren referred did not return to trial after inpatient phase, as referral was considered a trial end-
point. Recovered children were followed up fortnightly for 12 weeks and relapses recorded. A
supplementary feeding program accompanied the post-discharge follow-up, providing ready-
to-use supplementary foods when available.
Treatment protocol
Treatment followed the Burkina national CMAM guidelines in all aspects except the RUTF
dose. Half of the children received a reduced dose from the third treatment week onwards
(Table 1). Medical treatment included 7 days of amoxicillin for all children at admission (50–
100 mg/kg/day), albendazole at the second treatment visit for children�12 months (200 mg to
12–23-month-olds; 400 mg to�24-month-olds) and catch-up doses for missed routine vacci-
nations or vitamin A supplementation (100,000 IU to 6–11-month-olds; 200,000 IU to 12–
59-month-olds, every 6 months) at admission. Any illness, such as malaria, respiratory tract
infections, or diarrhoea, diagnosed during the study was treated according to national proto-
col. See S2 Text for the full protocol for the study.
Data collection and management
Two study teams were comprised of one nurse, three measurers, one food distributor, and one
supervisor per team. All team members were trained on research ethics and processes;
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standard operating procedures were defined, tested, and applied. Data were collected via tab-
lets using the Open Data Kit (ODK1 software), and continuous data monitoring and cleaning
were performed by a data manager under the supervision of the principal investigator. Elec-
tronic data were password protected, and field registries were kept in a locked office. Data
were de-identified prior to analysis.
Outcomes
The primary outcome was weight gain velocity (g/kg/day) from admission to discharge. Other
outcomes included weight gain velocity after two weeks, length of stay (LoS), discharge anthro-
pometrics, linear and MUAC growth, treatment outcome, morbidity, and relapses.
Weight gain velocity from admission to discharge was calculated by dividing the weight
gain (weight at discharge − weight at admission) in grams by the weight at admission in kilo-
grams and the LoS in days. Weight gain velocity after two weeks was measured as follows:
(weight at discharge − weight at visit 3 [in g])� (weight at admission [in kg])� (LoS − 14 [in
days]). Missing weights at visit 3 (60 in reduced and 58 in standard arm) were imputed using
mean weekly weight gained between an earlier visit (1 or 2) and later visit (4 or 5). The length
of the stay was calculated as the number of days spent from admission to either recovery, refer-
ral, nonresponse, false discharge, or last visit before defaulting, lost to follow-up, or death. Lin-
ear and MUAC growth were defined as gains in millimetres (exit measure − admission
measure)/week (LoS/7). A minimum acceptable mean rate of weight gain of 3.0 g/kg/day was
defined at the protocol stage as a quality cutoff for evaluating general program performance.
Nutritional recovery was defined as reaching a WHZ of�−2 for those admitted with a
WHZ<−3 only, or MUAC�125 mm for those admitted with a MUAC <115 mm only, or
both WHZ�−2 and MUAC�125 mm for those admitted with both WHZ <−3 and MUAC
<115 mm upon two consecutive visits and absence of any illness. Referrals included children
referred to inpatient care as a result of medical complications, >5% weight loss within three
weeks, or�100 g weight gain over four weeks in the absence of apparent illness. Nonresponse
included children not reaching anthropometric discharge criteria by 16 weeks of treatment
who were referred to inpatient care for further examinations. Defaulters were defined as hav-
ing missed three consecutive visits, but the child was confirmed to be alive. Transfers to health
centres not involved in the study were categorised as defaulters. ‘Lost to follow-up’ was defined
as having missed three consecutive visits without a known status of the child. False discharges
included children who were erroneously discharged as recovered or referred, but upon analy-
sis did not meet the criteria. Relapses were recorded over 12 weeks following recovery and
Table 1. RUTF dose in reduced and standard dose groups.
Weight (kg) Sachets/week Percent of reduction
Standard RUTF dose Reduced RUTF dose Reduced RUTF
dose
Admission to discharge Week 1–2 Week 3 to
discharge
From week 1–2 to week 3
3.0–3.4 8 8 7 13%
3.5–4.9 10 10 7 30%
5.0–6.9 15 15 7 53%
7.0–9.9 20 20 14 30%
10.0–14.9 30 30 14 53%
Abbreviation: RUTF, ready-to-use therapeutic foods.
https://doi.org/10.1371/journal.pmed.1002887.t001
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were defined as presenting a WHZ<−3 and/or a MUAC <115 mm, or any grade of bilateral
oedema.
Sample size
We assumed an expected mean difference in weight gain velocity between the two groups of
0.0 g/kg/day and a standard deviation (SD) of 2.6 g/kg/day with a non-inferiority margin of
0.5 g/kg/day. Assuming a power of 80% and a 5% significance level for a one-sided test, 335
children were needed in each group to demonstrate non-inferiority. To allow for dropout, the
total target sample size was 800 children. Applying a 0.22 SD difference as could be observed
in the main outcome with the calculated sample would allow us to detect a difference of 12%
in recovery, seven days in LoS, 0.4 mm/week in MUAC gain velocity, and 0.3 mm/week in
height gain velocity.
Data analysis
Baseline characteristics of the study population were summarised as percentages and means
(±SDs). Linear mixed models were used to compare primary and secondary outcomes of
weight, linear and MUAC growth velocities, LoS, and anthropometric endpoints. Results were
reported as differences of reduced dose from standard dose (reduced minus standard), with
positive values meaning greater estimates among reduced dose. For programmatic outcomes,
logistic mixed models were used to compare groups. Time to recovery was analysed using the
Cox proportional hazards model. Study sites and research teams were included in the mixed
models as random effects. Unadjusted models and models adjusted for sex, age, admission
measure of weight, height, MUAC, WHZ, wealth, LoS in treatment, and month of admission
were fitted. Adjustments were defined in the statistical analysis plan development stage prior
to data analysis (S3 Text). Model checking was based on residual plots and normal probability
plots, when applicable. All analyses were performed using STATA 15 (StataCorp).
Both intention to treat (ITT) and per protocol (PP) analyses were carried out for the main
outcome and key secondary outcomes. ITT analysis included all children admitted to the
study for whom an endpoint observation was available. PP analysis included children without
missed visits who, according to maternal recall, consumed >50% of the daily dose at all times
and excluded those who had received a wrong treatment dose or had been falsely discharged.
Interactions were only investigated in ITT analyses. Interactions between treatment and
age group (<12 months versus�12 months), sex, MUAC category (<115 versus�115 mm),
WHZ category (<−3 versus�−3), and stunting (height-for-age z-score [HAZ] < −2 versus
HAZ� −2) at admission were evaluated for the main outcome of weight gain velocity and the
key secondary outcomes of recovery, LoS and height gain velocity, by means of likelihood
ratio tests. Only significant interaction terms led to subgroup analyses.
‘Urban’ was defined as those living�30 minutes’ return trip from the regional capital city.
Low birth weight (<2,500 g) was confirmed from an official birth certificate or health card.
Household Food Insecurity Access Scale (HFIAS) was constructed according to FANTA indi-
cator guide [33].
Results
From October 17, 2016, to July 20, 2018, 1,186 children were diagnosed with SAM and
assessed for eligibility at 10 study sites. Of these, 802 (68%) children were eligible for the study
and randomised to standard or reduced RUTF dose (Fig 1). One child was excluded after ran-
domisation for not meeting the SAM criteria at admission. Therefore, 801 patients were
included in the trial: 402 in the reduced dose and 399 in the standard dose arm. Thirteen
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children defaulted or were referred immediately after admission; four and nine in reduced and
standard dose arms, respectively. Three children developed oedema (two in reduced and one
in standard dose arm) and were excluded from weight gain calculation. Only recovered chil-
dren continued to the post-discharge follow-up, contributing to the post-discharge outcome
analyses including relapse rate (Fig 1).
Randomisation resulted in baseline equivalence between the reduced and standard dose
arms with respect to potential confounders (Table 2). The mean age at admission was 13.4
months, 49% were boys, and the mean admission weight was 6.2 kg. At visit 3, no children
were<3.5 kg, 5% were 3.5–4.9 kg, 61% were 5.0–6.9 kg, 30% were 7.0–9.9 kg, and 4% were
10.0–14.9 kg. Caregivers were, on average, 28 years of age, 76% had no formal education, and
88% were categorised as food secure.
Primary outcome
The mean weight gain velocity from admission to discharge was 3.4 g/kg/day in both groups
in ITT analysis (Δ 0.0 g/kg/day; 95% CI −0.4 to 0.4). Non-inferiority of the reduced dose could
be confirmed in both ITT (inferiority rejected: p = 0.013) and PP (inferiority rejected:
p = 0.019) for this main outcome (Fig 2). No differences were found in weight gain velocity in
PP analysis (Δ 0.2 g/kg/day; 95% CI −0.5 to 0.8), in ITT among recovered only (Δ −0.1 g/kg/
day; 95% CI −0.6 to 0.4), referrals (Δ 0.5 g/kg/day; 95% CI −0.6 to 1.5), or defaulters (Δ −0.3 g/
kg/day; 95% CI −1.3 to 0.8) (Table 3). No interactions were found between treatment and sex,
age, MUAC category, WHZ category, or stunting status at admission. In general, mean weight
Fig 1. Patient flowchart. FU, follow-up; ITT, intention to treat; PP per protocol; RUTF, ready-to-use therapeutic food; SAM, severe acute malnutrition.
https://doi.org/10.1371/journal.pmed.1002887.g001
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gain velocity was high at the start of the treatment and decreased rapidly (Fig 3). When enter-
ing third treatment week, 27% of children still had SAM (WHZ <−3 and/or MUAC <115
mm): 108 children in the reduced and 106 children in the standard group.
Weight gain velocity after the first two weeks of treatment (in ITT) was significantly differ-
ent between groups, with a mean of 2.3 g/kg/day with reduced versus 2.7 g/kg/day with stan-
dard dose (Δ −0.4 g/kg/day; 95% CI −0.8 to −0.02). Results comparing the MUAC gain
velocity between reduced and standard doses mirrored the results obtained with weight gain
velocity (Table 3). Adjusted analysis yielded similar results that are found in S1 Table.
Secondary outcomes
No differences were found in anthropometry at discharge between study arms in the unad-
justed model (all p> 0.2). However, when using the adjusted model (adjusting for sex, age,
admission measure of weight, MUAC, WHZ and height, month of admission, LoS, and wealth
index), height at discharge was significantly smaller in the reduced dose arm (Table 4). This
difference in height of 0.1 cm could still be observed 3 months post-recovery, although the dif-
ference was then no longer significant (p = 0.33). Weight, MUAC, weight-for-age z-score
(WAZ), WHZ, and HAZ were not different at three months post-recovery.
The median LoS was 56 days (interquartile range [IQR] 35–91) in both arms. The WHZ
category was an effect modifier (interaction, p = 0.028) whereby children who were admitted
Table 2. Baseline characteristics of 801 children with SAM, randomised to reduced or standard RUTF dose.
Characteristic n Reduced RUTF Standard RUTF
Age, months 801 13.3 ± 8.6 13.4 ± 8.9
Male, % (n) 801 49.5 (199) 49.4 (197)
Weight, kg 801 6.2 ± 1.2 6.2 ± 1.4
Height, cm 801 69.1 ± 7.4 69.1 ± 8.0
MUAC, mm 801 113 ± 7 113 ± 7
WHZ 801 −3.1 ± 0.7 −3.1 ± 0.7
HAZ 801 −2.4 ± 1.3 −2.4 ± 1.3
WAZ 801 −3.5 ± 0.8 −3.5 ± 0.8
Admission criteria, % (n) 801
WHZ only 27 (107) 26 (102)
MUAC only 39 (156) 38 (153)
WHZ and MUAC 35 (139) 36 (144)
Low birth weight, % (n) 502 23 (60) 21 (50)
Urban, % (n) 801 15 (59) 14 (54)
Health centre�30-minute return trip, % (n) 801 39 (155) 37 (149)
Caregiver’s age 801 27.8 ± 7.6 27.6 ± 7.9
Mother has no formal education, % (n) 801 76 (305) 75 (301)
HFIAS category, % (n) 801
Food secure 88 (353) 88 (350)
Mild food insecurity 9 (35) 9 (34)
Moderate or severe food insecurity 3 (14) 4 (15)
Open defecation, % (n) 801 77 (311) 75 (298)
All values are means ± SD unless otherwise indicated.
Abbreviations: HAZ, height-for-age z-score; HFIAS, Household Food Insecurity Access Scale; MUAC, mid-upper
arm circumference; RUTF, ready-to-use therapeutic food; SAM, severe acute malnutrition; SD, standard deviation;
WAZ, weight-for-age z-score; WHZ, weight-for-height z-score.
https://doi.org/10.1371/journal.pmed.1002887.t002
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Fig 2. Difference in mean weight gain velocity (g/kg/day and 90% CI) in children with SAM randomised to reduced dose
compared with standard dose in ITT and PP confirming non-inferiority. ITT, intention to treat; PP, per protocol; SAM,
severe acute malnutrition.
https://doi.org/10.1371/journal.pmed.1002887.g002
Table 3. Weight and MUAC gain velocity of children with SAM randomised to reduced or standard RUTF dose in unadjusted model.
Outcome Reduced RUTF Standard RUTF Difference
(95% CI)
p-value
Admission to Discharge n mean ± SD n mean ± SD
Weight gain velocity (g/kg/day)
ITT 396 3.4 ± 3.1 389 3.4 ± 3.1 0.0 (−0.4 to 0.4) 0.92
PP1 200 4.3 ± 3.4 223 4.1 ± 3.6 0.2 (−0.5 to 0.8) 0.58
Recovered 212 4.9 ± 2.6 221 4.9 ± 2.5 −0.1 (−0.6 to 0.4) 0.73
Referred 74 0.9 ± 3.4 78 0.4 ± 3.0 0.5 (−0.6 to 1.5) 0.37
Defaulted 46 2.5 ± 1.9 26 2.7 ± 2.7 −0.3 (−1.3 to 0.8) 0.64
MUAC gain velocity (mm/week)
ITT 398 1.8 ± 1.8 390 1.9 ± 1.9 −0.1 (−0.3 to 0.2) 0.58
PP1 201 2.4 ± 2.1 224 2.4 ± 2.1 −0.1 (−0.5 to 0.3) 0.78
After Two Weeks
Weight gain velocity (g/kg/day)
ITT 376 2.3 ± 2.6 368 2.7 ± 2.9 −0.4 (−0.8 to −0.02) 0.041
PP1 188 2.7 ± 2.9 207 3.1 ± 3.4 −0.4 (−1.0 to 0.2) 0.22
MUAC gain velocity (mm/week)
ITT 378 1.1 ± 1.7 368 1.4 ± 1.9 −0.2 (−0.5 to −0.001) 0.051
PP1 189 1.6 ± 1.9 207 1.8 ± 2.2 −0.2 (−0.6 to 0.2) 0.27
Data are mean ± SD and mean difference (95% CI) when using linear mixed models, with study site and team as random effects.
1PP (per protocol) includes children that had no missed visits, that consumed >50% of daily dose throughout treatment, that were not falsely discharged, and that
received the correct RUTF dose throughout treatment.
Abbreviations: ITT, intention to treat; MUAC, mid-upper arm circumference; PP, per protocol; RUTF, ready-to-use therapeutic food; SAM, severe acute malnutrition.
https://doi.org/10.1371/journal.pmed.1002887.t003
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with a WHZ�−3 and treated with the reduced dose had a LoS 6.9 days (95%CI −0.1 to 13.9;
p = 0.055) longer than those treated with the standard dose. No difference was found in the
LoS of children admitted with WHZ<−3 between reduced and standard doses. No effect
modification for LoS was observed between treatment and age, sex, MUAC category, or stunt-
ing at admission. The recovery rate was similar in both arms: 52.7% in reduced dose and
55.4% in standard dose (Δ −2.6%; 95% CI −9.5 to 4.3) (Table 5). Cox proportional hazards
model showed no difference (p = 0.54) in the time to recovery between the two arms (Fig 4).
No significant interactions were found for recovery. No differences were found in the propor-
tion of children referred (19.2% and 20.1%), defaulting (12.2% and 8.5%), nonresponding
(12.7% and 12.5%), and relapsed (2.4% and 1.8%) between reduced and standard RUTF dose
arms, respectively (Table 5). PP analysis provided similar results and is found in S2 Table. The
number or duration of illnesses between study arms did not differ (p> 0.2): 60% of children
Fig 3. Weekly weight gain velocity (g/kg/day) of children with SAM randomised to reduced or standard RUTF dose, modeled using the mean weight
of each group per visit. The first two weeks, when both groups were receiving the standard dose, were plotted apart in order not to mask any effect on
weight gain after the reduction came into effect at week 3. A lowess curve was fitted with 224 points calculated between the weeks ranging from 3 to 16.
RUTF, ready-to-use therapeutic food; SAM, severe acute malnutrition.
https://doi.org/10.1371/journal.pmed.1002887.g003
Table 4. Anthropometry at discharge of children with SAM randomised to reduced or standard RUTF dose with difference (95% CI) in unadjusted and adjusted
ITT analysis.
Outcome n Reduced RUTF Standard RUTF Unadjusted Adjusted�
Difference (95% CI) p-value Difference
(95% CI)
p-value
Weight, kg 785 7.3 ± 1.4 7.3 ± 1.5 −0.0 (−0.2 to 0.2) 0.74 −0.0 (−0.1 to 0.03) 0.25
Height, cm 788 71.5 ± 7.0 71.6 ± 7.5 −0.1 (−1.1 to 0.9) 0.87 −0.1 (−0.2 to −0.03) 0.013
MUAC, mm 788 125.2 ± 8.1 125.9 ± 8.5 −0.7 (−1.9 to 0.4) 0.21 −0.7 (−1.7 to 0.3) 0.17
WHZ 784 −2.0 ± 0.9 −1.9 ± 1.0 −0.0 (−0.2 to 0.1) 0.64 −0.0 (−0.2 to 0.1) 0.63
HAZ 788 −2.3 ± 1.2 −2.3 ± 1.3 0.0 (−0.2 to 0.2) 0.93 −0.0 (−0.1 to 0.1) 0.60
WAZ 785 −2.7 ± 0.9 −2.6 ± 1.0 −0.0 (−0.1 to 0.1) 0.82 −0.0 (−0.1 to 0.1) 0.51
Data are mean ± SD and mean difference (95% CI) when using linear mixed models with study site and team as random effects.
�Adjusted for sex, age, admission measure of weight, MUAC, WHZ and height, month of admission, LoS, and wealth index.
Abbreviations: HAZ, height-for-age z-score; ITT, intention to treat; LoS, length of stay; MUAC, mid-upper arm circumference; RUTF, ready-to-use therapeutic food;
SD, standard deviation; WAZ, weight-for-age z-score; WHZ, weight-for-height z-score.
https://doi.org/10.1371/journal.pmed.1002887.t004
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had a respiratory illness, 38% had malaria, and 52% had diarrhoea at some point after admis-
sion. During the intervention, two children died (one in each group), one was lost to follow-up
(standard dose), and 24 were falsely discharged (12 in each group).
Height gain velocity was lower in children who received the reduced dose (2.6 mm/week)
than the standard dose (2.8 mm/week) (Δ −0.2 mm/week; 95% CI −0.4 to −0.04). Age was an
effect modifier (interaction, p = 0.019): the height gain of children under 12 months of age was
2.8 mm/week with reduced dose and 3.1 mm/week with standard dose (Δ −0.4 mm/week; 95%
CI −0.6 to −0.2). Similarly, from admission to discharge, HAZ increased by 0.05 SD with
reduced and 0.09 SD with standard RUTF dose (Δ −0.04 SD; 95% CI −0.09 to 0.002). Again,
age was an effect modifier (interaction, p = 0.016): children under 12 months of age had 0.00
SD catch-up in HAZ with reduced dose compared with 0.09 SD with standard dose (Δ −0.09
SD; 95% CI −0.15 to −0.03) (Table 6). Height gain or HAZ catch-up did not differ between
RUTF dose among children�12 months. Adjusted analysis provided similar results that are
found in S3 Table.
Discussion
Evidence is needed to inform policy on the optimisation of treatment of uncomplicated SAM.
The current trial investigated the efficacy of reducing the RUTF dose after two weeks and
showed that there was no effect on the total weight or MUAC gain velocity, recovery, or LoS in
Table 5. Programmatic outcomes of children with SAM randomised to reduced or standard RUTF dose with risk difference (95% CI) in unadjusted ITT analysis.
Outcome Reduced RUTF Standard RUTF Difference
(95% CI)
p-value
n median [IQR] n median [IQR]
LoS, days 402 56 [35–91] 399 56 [35–91] 0.8 (−3.7 to 5.3) 0.73
Subgroup analysis by
WHZ at admission 402 399 0.028�
<−3 238 56 [35–84] 238 56 [35–98] −3.3 (−9.1 to 2.5) 0.26
�−3 164 56 [35–91] 161 49 [35–77] 6.9 (−0.1 to 13.9) 0.055
% (n) % (n)
Recovery 402 52.7 (212) 399 55.4 (221) −2.6 (−9.5 to 4.3) 0.45
Referral 402 19.2 (77) 399 20.1 (79) −0.7 (−6.2 to 4.8) 0.80
Weight loss 402 12.9 (52) 399 15.3 (61) −2.4 (−7.2 to 2.5) 0.34
Stagnant weight 402 4.0 (16) 399 3.8 (15) 0.0 (−2.6 to 3.0) 0.88
Medical complication 402 2.2 (9) 399 1.0 (4) 1.2 (−0.5 to 2.8) 0.18
Defaulter 402 12.2 (49) 399 8.5 (34) 3.7 (−0.5 to 7.9) 0.088
Lost to follow-up 402 0.0 (0) 399 0.3 (1) NA
Nonresponse 402 12.7 (51) 399 12.5 (50) −0.2 (−4.4 to 4.8) 0.95
Died 402 0.3 (1) 399 0.3 (1) NA
False discharge 402 3.0 (12) 399 3.0 (12) −0.0 (−2.4 to 2.3) 0.99
Relapse 212 2.4 (5) 221 1.8 (4) 0.5 (−2.1 to 3.2) 0.69
Data are median [IQR] for LoS and percentage (n) for other outcomes and mean difference (95% CI) for the differences. Linear mixed models were used, with study site
and team as random effects.
�p for interaction. Interactions were tested in ITT for sex, age, MUAC category, WHZ category, and stunting status at admission, and only significant terms (p< 0.05)
and subsequent subgroups analysis are reported.
Abbreviations: IQR, interquartile range; ITT, intention to treat; LoS, length of stay; MUAC, mid-upper arm circumference; RUTF, ready-to-use therapeutic food; WHZ,
weight-for-height z-score.
https://doi.org/10.1371/journal.pmed.1002887.t005
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treatment. However, the linear growth of children receiving the reduced dose was significantly
slower, particularly among the youngest group of<12-month-old children.
The mean weight gain velocity of 3.4 g/kg/day observed from admission to discharge is in
line with those reported in earlier CMAM studies [5–20]. While non-inferiority was confirmed
for weight gain velocity from admission to discharge, the difference in weight gain after two
weeks was 0.4 g/kg/day (p = 0.041) between children receiving the reduced dose of RUTF
(mean 2.3 g/kg/day) compared with the standard dose (mean 2.7 g/kg/day). This finding sug-
gests that the rapid weight gain in the first two weeks, when all children received the standard
dose, masks the small negative effect the reduced dose has on the subsequent growth of chil-
dren. The weight gain velocity during treatment shows a quickly decreasing pattern, in which
the first weeks represent high catch-up in weight. From the fifth treatment week onward, the
weight gain velocity drops to<2 g/kg/day and resembles that observed in MAM treatment
programs [34–36]. From the eighth week onward, the weight gain velocity was approximately
1 g/kg/day, similar to normal weight gain velocity for a healthy one-year-old child [37]; this
despite continuing to receive RUTF. However, recovery continues throughout treatment until
the 16th week, when those not yet recovered were considered ‘nonresponse’ to treatment.
Linear growth observed in the trial (2.6 mm/week with reduced dose and 2.8 mm/week
with standard dose) is in line with other CMAM studies [5,6,9,10,16,19,38] and with the 2.8
mm/week growth rates expected in healthy 13-month-old children [39]. However, the reduced
dose slowed down the linear growth of children by 0.2 mm/week (95% CI 0.04 to 0.4;
p = 0.015). Whether this difference is clinically significant remains questionable. In general,
linear growth is considered at least as important, if not more important, than weight gain for
the healthy growth of children [40]. A follow-up study of children recovered from SAM found
that seven years later, these children had similar weight- and BMI-for-age, but significantly
Fig 4. Weekly recovery among children with SAM randomised to reduced or standard RUTF dose. RUTF, ready-to-use therapeutic
food; SAM, severe acute malnutrition.
https://doi.org/10.1371/journal.pmed.1002887.g004
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lower HAZ and absolute height compared with their siblings and community controls [41].
HAZ and absolute height are both predictors of chronic disease in later life [42]. In our trial,
the mean HAZ was −2.4 at admission, and it increased by 0.05 and 0.09 with the reduced and
standard doses, respectively (Δ −0.04 HAZ; 95% CI −0.09 to 0.002; p = 0.063). On the contrary,
among children treated for MAM, HAZ decreased by 0.17 during 12 weeks of supplementary
feeding in Burkina Faso [34]. Reasons for different linear catch-up growth between children
with MAM and SAM could include therapeutic food quality and quantity. Linear growth
requires micronutrients, in particular, type 2 micronutrients such as zinc, magnesium, and
potassium [43], which are provided by RUTF [3] at much higher levels than are available in
local diets [44]. A reduction in the RUTF dose or quality possibly reduces the quantity and
density of these nutrients and by consequence may affect linear growth.
The observed recovery rates (52.7% with reduced dose and 55.4% with standard dose) are
low but are explained by the strict application of referral criteria in our trial, and that referral
was considered an effective study endpoint. When using the SPHERE calculation method [45]
excluding referred and false discharge, recovery rates were 68% in the reduced dose and 72% in
standard dose, somewhat under the recommended >75%. Up to 20% of children were referred
primarily as a result of weight loss or stagnant weight, which may not often be identified in rou-
tine programs. Nevertheless, the similar referral rate between study arms suggests these referrals
are not related to a dose effect. In a post hoc analysis, weight loss was associated with higher
numbers and longer duration of illness episodes. Episodes of infection are known to drive
undernutrition via appetite loss, reduced nutrient absorption, nutrient losses, diversion of nutri-
ents to inflammatory responses, and tissue repair [46]. Open defecation was practised by 76% of
Table 6. Height gain velocity (mm/week) and HAZ change (SD) from admission to discharge of children with SAM randomised to reduced or standard RUTF dose
and difference (95% CI) in unadjusted model.
Outcome Reduced RUTF Standard RUTF Difference
(95% CI)
p-value
n mean ± SD n mean ± SD
Height gain velocity (mm/week)
ITT 398 2.6 ± 1.3 390 2.8 ± 1.3 −0.2 (−0.4 to −0.04) 0.015
PP1 201 2.5 ± 1.3 224 2.9 ± 1.4 −0.3 (−0.6 to −0.1) 0.009
Subgroup analysis by
Admission age 398 390 0.019�
<12 months 244 2.8 ± 1.2 235 3.1 ± 1.1 −0.4 (−0.6 to −0.2) <0.001
�12 months 154 2.3 ± 1.3 155 2.2 ± 1.2 0.03 (−0.2 to 0.3) 0.85
HAZ change (SD)
ITT 398 0.05 ± 0.35 390 0.09 ± 0.32 −0.04 (−0.09 to 0.002) 0.063
PP1 201 0.06 ± 0.31 224 0.10 ± 0.27 −0.04 (−0.10 to 0.01) 0.12
Subgroup analysis by
Admission age 398 390 0.016�
<12 months 244 0.00 ± 0.39 235 0.09 ± 0.35 −0.09 (−0.15 to −0.03) 0.003
�12 months 154 0.13 ± 0.25 155 0.10 ± 0.25 0.03 (−0.05 to 0.10) 0.47
Data are shown as mean ± SD and mean difference (95% CI) using linear mixed models, with study site and research team as random effects.
�p for interaction. Interactions were tested in ITT for sex, age, MUAC category, WHZ category, and stunting status at admission, and only significant terms (p< 0.05)
and subsequent subgroups analysis are reported.
1PP (per protocol) includes children that had no missed visits, that consumed >50% of the daily dose throughout treatment, that were not falsely discharged, and that
received the correct RUTF dose throughout treatment.
Abbreviations: HAZ, height-for-age z-score; ITT, intention to treat; MUAC, mid-upper arm circumference; PP, per protocol; RUTF, ready-to-use therapeutic food; SD,
standard deviation; WHZ, weight-for-height z-score.
https://doi.org/10.1371/journal.pmed.1002887.t006
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households, indicating a poorly sanitised home environment with high risk of exposure to path-
ogens [47]. This could partially explain a proportion of illness episodes and the relatively high
proportion of cases with weight loss or stagnant weight. Beyond acute illness, environmental
enteric dysfunction is another potential driver of suboptimal recovery [46].
In the current trial, the reduced RUTF dose had no negative effects on children�12
months of age but slowed down the height gain of children <12 months of age. Bahwere and
colleagues (2016) found that providing milk-free RUTF had no adverse effect among children
with SAM�24 months of age, while children <24 months of age had a significantly lower
recovery rate. Seemingly, younger children are somewhat more sensitive to changes in RUTF
quantity and quality, possibly requiring standard treatment in order to gain the full benefit
from SAM treatment. Whether separate protocols should be considered for different age
groups remains a question requiring operational feasibility, effectiveness, and cost estimations.
In the context of the current global transition from a focus on purely ensuring the survival
of children to actually enabling them to thrive, the quest is emerging in the malnutrition com-
munity to go beyond recovery and seek to optimise the functional and long-term outcomes of
children treated for SAM [41,48]. This will require looking at body composition, micronutri-
ent status, cognitive development, and other long-term outcomes. At the same time, the
resources are limited and cost-efficiency should be taken into account and existing and new
investments evaluated against the benefits they can bring.
The main strength of the study is the individually randomised design with few dropouts
immediately after admission, which reduces confounding and enables a causal analysis of the
effect of the reduced RUTF dose on the weight gain of uncomplicated SAM. The field study
was implemented by well-trained and experienced research staff who were responsible for the
diagnosis, treatment, and discharge of children with SAM. The number of patients per day was
also limited to enable thorough care and follow-up of the study children.
As with all studies, there are limitations. First, although we did not reveal the study arm to
participants, it was not possible to blind them to the RUTF dose received. However, because
the daily dose prescribed to children in both arms depended on the weight of the child, we did
not expect caregivers to be fully aware of the treatment allocation. With the exception of the
RUTF distributor, the research staff were blinded to the dose. Second, we excluded and
referred to inpatient care all children who did not pass the appetite test at admission. While
officially a referral criterion, the appetite test is not always implemented in the field. It is possi-
ble that children who in routine practice fail the appetite test have a slower weight gain at the
beginning of treatment and thereafter an inferior response to a reduced dose after two weeks.
The study findings are only generalisable to a nonemergency context with relatively good food
security and where SAM cases are primarily very young (<24 months of age). However, further
research is needed to corroborate these findings in a routine program with fewer resources and time
per patient, and to translate these finding to an emergency context or to older-aged SAM cases.
In conclusion, reducing the RUTF dose prescribed to children with SAM after two weeks
does not appear to affect the total weight or MUAC gain velocity, recovery rate, nor the LoS in
treatment. However, the linear growth of children became slower with the RUTF reduction,
especially in young children. Before considering a reduction of RUTF during SAM treatment,
an effectiveness study in a routine program setting is needed to confirm the results.
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